Modena said it is preparing to apply for emergency authorization in the U.S. and Europe on Nov. 30 to approve the new crown vaccine they have developed.
The results of Modena’s post-study studies show that the vaccine is 94.1% effective and that there are no serious safety concerns. Modena CEO, Stephen Banser, is very optimistic about the vaccine.
Modena CEO Stephen Banser said, “We feel very confident about the 94.1% efficacy that we will be filing with the FDA today. But the most exciting news for me yesterday, when I learned about the data, was about the severe cases. Because if we can prevent severe cases, it means fewer hospitalizations and no deaths. I believe this will change the trend of this pandemic.”
Modena also reported that the vaccine’s effectiveness was consistent across age, ethnic, racial, and gender demographics and that the vaccine had a 100 percent success rate of preventing severe illness in the new canopy epidemic, which has killed nearly 1.5 million people.
Of the more than 30,000 volunteers who participated in the trial, 196 were infected with the new coronavirus, 185 of whom received a placebo and only 11 of whom received the vaccine. Modena reported 30 severe cases, all of whom were in the placebo group, meaning the vaccine was 100% effective in preventing the development of severe symptoms.
Modena’s vaccine product is the second vaccine that is expected to receive a U.S. emergency use authorization this year, following an injection jointly developed by Pfizer and BioNTech. Pfizer’s vaccine has a trial efficacy of 95 percent.
Recent Comments